KPV

Why scientists study it

• Since the early 1990s it has been tested as the shortest tail piece of α-MSH (positions 11 to 13) that keeps the hormone’s effect against inflammation, without its pigment and wider hormone effects.
• In mice with colitis and in colon lining cells, scientists have tested how it enters gut cells through the PepT1 carrier and how it changes inflammation signals driven by NF-κB.
• It has been packed into swallowed nanoparticles aimed at the gut, and it builds on decades of cell and animal work on how α-MSH peptides affect inflammation signals in macrophages, neutrophils and lining cells.

Three studies to know

Dalmasso et al., 2008 · Gastroenterology

Dalmasso and colleagues found that gut cells take in KPV through the PepT1 carrier. In mice with colitis, this went with lower signs of gut inflammation. Read the paper

Kannengiesser et al., 2008 · Inflammatory Bowel Diseases

Kannengiesser and colleagues tested KPV in several mouse models of inflammatory bowel disease. They reported that it could work against inflammation in those animals. Read the paper

Luger & Brzoska, 2007 · Annals of the Rheumatic Diseases

This review covers peptides related to α-MSH, including three-part tail pieces such as KPV. It treats them as a class of research compounds that calm inflammation and adjust the immune system. Read the paper

Safety and legal status

• KPV is an experimental research compound. As of 2026 it is not approved by the FDA, the EMA or the MHRA for treating people.
• The World Anti-Doping Agency does not list KPV or α-MSH by name. Its class S0 bans drug-like substances that no health authority has approved, named or not.
• Supplied for laboratory research only. It is not for human use.